Ilyang to conduct Phase 2 study of new leukemia dug in India, Thailand
Developed by Ilyang, the drug is believed to be 30 times more potent than Glivec, a popular anti-leukemia medicine. If successful, it is expected to change the landsca...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
